AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03022812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck-specific exercise
Description: Neck-specific exercise
Study NCT01926132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid 10g/20ml
Description: ascorbic acid 10g/20cc intravenous injection for 40mins
Study NCT01926132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 150ml
Description: Normal Saline 150ml intravenous injection for 40mins
Study NCT04849637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: Oral supplementation of virgin coconut oil to COVID-19 patients
Study NCT02248896 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT02248896 — intervention group
Intervention type: DRUG
Intervention: Other angiotensin-receptor blockers (ARBs)
Study NCT03022812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise
Description: Neck-specific exercise
Study NCT02248896 — intervention group
Intervention type: DRUG
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs)
Study NCT02248896 — intervention group
Intervention type: DRUG
Intervention: Other major antihypertensive medication classes
Description: e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
Study NCT00399035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: oral tablet
Study NCT04041908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Product
Description: 2 sachets per day
Study NCT00399035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion
Study NCT01204333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endovascular thrombolysis
Description: Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
Study NCT01204333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
Study NCT00399035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion
Study NCT00399035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX (Capecitabine and Oxaliplatin)
Description: intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
Study NCT04261452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: isokinetic dynamometer
Description: Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.~Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values.
Study NCT04261452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiopulmonary Exercise Test
Description: All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.~The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population.
Study NCT04261452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Functional Capacity Tests
Description: The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.~The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test.
Study NCT04261452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung Function Test
Description: Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a Pitot-tube based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery.
Study NCT04261452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Doppler Echocardiography
Description: The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.
Study NCT04261452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Anthropometry and Body Composition
Description: Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.~Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM).
Study NCT00304915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Interventions
Description: Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
Study NCT01078714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bumetanide
Description: Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
Study NCT01078714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bumetanide
Description: Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
Study NCT03819218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 cream
Description: MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
Study NCT03104998 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Coenzyme Q10
Description: 200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
Study NCT00821665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose consumption
Description: Sucrose
Study NCT00821665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: water consumption
Description: water
Study NCT03002103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1
Study NCT03002103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT03002103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT03002103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Study NCT03002103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Study NCT00598715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stent
Description: Sirolimus-eluting stent will be implanted
Study NCT00598715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent
Description: Paclitaxel-eluting stent will be implanted
Study NCT04262661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0472-0147
Description: Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
Study NCT04262661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.
Study NCT04262661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0472-0147)
Description: Part 1: A single dose of placebo, dose increased in each cohort.
Study NCT03412786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bcl-Xl_42-CAF09b vaccine
Description: The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
Study NCT01563419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indicator magnifying window (Izumi Planning Co.)
Description: IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens
Study NCT04323241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled cord traction
Description: In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
Study NCT04542265 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.
Study NCT04542265 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.
Study NCT01664221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
Study NCT01664221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
Study NCT02043665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21/pembrolizumab
Study NCT04413136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-ORLA
Study NCT04413136 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT01630681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based stepped care
Description: Interactive support and Cognitive Behavioral Therapy
Study NCT01268605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with a dentin bonding agent (DBA)
Description: Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
Study NCT01268605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with a resin modified glass ionomer liner (RMGI)
Description: Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
Study NCT02882685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-y gastric bypass
Study NCT02882685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single anastomosis gastric bypass
Study NCT04746300 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
Study NCT04746300 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood samples will be taken for additional translational research
Study NCT01949961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for \~30 minutes, using a Bracco infusion pump.
Study NCT01949961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham ultrasound
Description: Mounting the ultrasound headframe but connecting this to a non-operative channel
Study NCT02848911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM11
Description: Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
Study NCT00399035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XELOX (Capecitabine and Oxaliplatin)
Description: intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
Study NCT00399035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cediranib Placebo
Description: oral tablet
Study NCT00620997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine drops 0.05%
Description: topical, 0.05% drops, PRN continuously for up to 7 days
Study NCT00620997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline drops
Description: saline drops continuously PRN for up to 7 days
Study NCT02756377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetylpyridinium chloride mouthwash
Description: cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Study NCT02756377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Study NCT04114422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seven-day preoperative exercise training program
Description: The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
Study NCT01852071 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of autologous EFS-ADA LV CD34+ (OTL-101)
Description: autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
Study NCT01852071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan is used for non-myeloablative conditioning
Study NCT01852071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-ADA ERT
Description: PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
Study NCT01232712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ImMucin, hGM-CSF
Description: * Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~* After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~* In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected.
Study NCT01236001 — intervention group
Intervention type: DRUG
Intervention: Lacosamide
Study NCT00479635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: 160 mg/m2 every three weeks for six cycles
Study NCT00479635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: 160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
Study NCT00591708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage containing calcium citrate malate
Description: Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
Study NCT00591708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage fortified with calcium citrate malate
Description: Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
Study NCT04238793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLS-2031
Description: KLS-2031 administered by transforaminal epidural injection
Study NCT04238793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9%) administered by transforaminal epidural injection
Study NCT03430258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flow nasal cannula
Description: high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier
Study NCT03430258 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional oxygen therapy
Description: Conventional oxygen therapy
Study NCT02714660 — intervention group
Intervention type: OTHER
Intervention: none, observational study
Study NCT02091076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk fibroin with bioactive coating layer dressing
Study NCT02091076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bactigras wound dressing
Study NCT03647683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Compassion
Description: Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus.
Study NCT03647683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance
Description: Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus.
Study NCT02219724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOXR0916
Description: MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
Study NCT02065024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: b-cryptoxanthin plus phytosterols
Study NCT02065024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: b-cryptoxanthin plus phytosterols
Study NCT00978042 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Juvéderm® VOLUMA XC
Description: Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
Study NCT00978042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLUMA XC
Description: Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
Study NCT03110549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-607
Study NCT03110549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02140619 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: multiple health education interventions